Orasure Technologies IncOSUR

OraSure Technologies Inc. reported a $22.4 million net loss for the quarter ending 31 March 2026, on revenue of $27.9 million, while burning $13.9 million in operating cash, according to the company’s latest 10-Q filing. The loss equated to diluted earnings per share of -$0.32, with 69.7 million diluted shares in circulation. The filing shows the company’s cash and cash equivalents stood at $177 million, while total assets weighed in at $379.2 million against liabilities of $65.8 million. Inventory totalled $30.3 million, down $714,000 from the prior quarter, and the company booked $13.7 million in R&D expense alongside $913,000 in capital expenditure.

OraSure describes itself as a global outfit that ‘empowers the world to improve health and wellness by providing access to accurate, essential information,’ but its product pages quietly note that several of its signature oral-fluid drug and alcohol testing lines-QED, Intercept, Intercept i2, Intercept i2he, Auto-Lyte and Micro-Plate-are ‘no longer available for sale or distribution.’ The company’s site still hosts a suite of diagnostics and collection devices, including the OraSure HIV-1 Oral Specimen Collection Device, yet the practical shelf offering appears to have shrunk materially.

On 11 June 2026, OraSure filed an 8-K announcing no material transaction or asset sale, merely restating the operational status of its products. The same day, insiders filed a cluster of Form 4s detailing routine share movements, a sequence that typically raises eyebrows when cash burn is accelerating and near-term revenue visibility is thin. The company’s product support pages still host manuals and FAQs for legacy devices, while its terms page specifies that shipments leave the factory on an EXW Incoterms 2020 basis-meaning the customer bears the risk and freight once the goods leave the facility.

The company’s XBRL company facts feed confirms the headline numbers but offers no segment-level breakdown, guidance, or forward-looking disclosures. The SEC submissions index confirms the filings are current and accessible, yet the absence of an earnings call transcript or investor deck suggests management is either supremely confident in radio silence or supremely aware that silence is the better part of valour.

OraSure’s filing rail shows no share buybacks during the quarter, and the cash burn rate implies the $177 million balance would fund roughly twelve months of operating losses at the current clip. Inventories are falling, which can signal lean inventory management or soft demand; either way, the evidence doesn’t say which. The website rail still flogs an ‘accurate diagnosis in 20 minutes’ narrative, but the product rail’s ‘no longer available’ badges are the louder signal.

There is no evidence in the source pack of an imminent FDA approval, major distribution win, or new product launch that would materially change the revenue trajectory. The company’s own product pages now carry ‘no longer available’ stamps, and the support pages remain intact for legacy devices, indicating a slow wind-down rather than a pivot. Until the company files a material update or provides segment-level commentary, the market’s information set is broadly the quarterly 10-Q and the shrinking product shelf.